Virologically suppressed switch to Dolutegravir/Lamivudine 2-Drug regimen versus switch to commonly prescribed 3-Drug regimens in the United States
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Virologically suppressed switch to Dolutegravir/Lamivudine 2-Drug regimen versus switch to commonly prescribed 3-Drug regimens in the United States ; volume:21 ; number:1 ; day:26 ; month:10 ; year:2024 ; pages:1-10 ; date:12.2024
AIDS research and therapy ; 21, Heft 1 (26.10.2024), 1-10, 12.2024
- Creator
-
Pierone, Gerald
Fusco, Jennifer S.
Brunet, Laurence
Vannappagari, Vani
Sarkar, Supriya
Henegar, Cassidy E.
Wyk, Jean van
Wohlfeiler, Michael B.
Mills, Anthony
Fusco, Gregory P.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12981-024-00668-7
- URN
-
urn:nbn:de:101:1-2501162105042.256819475747
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Pierone, Gerald
- Fusco, Jennifer S.
- Brunet, Laurence
- Vannappagari, Vani
- Sarkar, Supriya
- Henegar, Cassidy E.
- Wyk, Jean van
- Wohlfeiler, Michael B.
- Mills, Anthony
- Fusco, Gregory P.
- SpringerLink (Online service)
Other Objects (12)
Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir Plus Lamivudine for Switch Therapy in Patients with HIV-1 Infection: A Real-World Cohort Study
Photothermal switch of drug release from polydopamine-modified nanosheets
Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study
HIV-1 pretreatment and acquired antiretroviral drug resistance before tenofovir/ lamivudine /dolutegravir (TLD) roll-out in Mozambique
Drug-Induced Morphology Switch in Drug Delivery Systems Based on Poly(2-oxazoline)s
How to switch a master switch
HIV Treatment with the Two-Drug Regimen Dolutegravir Plus Lamivudine in Real-world Clinical Practice: A Systematic Literature Review
Switch Hitters
Comparing Real-World Healthcare Costs Associated with Single-Tablet Regimens for HIV-1: The 2-Drug Regimen Dolutegravir/Lamivudine vs. Standard 3- or 4-Drug Regimens
Analysis of patients’ request to switch from a generic drug to the original drug in external prescriptions
Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir Plus Lamivudine for Switch Therapy in Patients with HIV-1 Infection: A Real-World Cohort Study
Photothermal switch of drug release from polydopamine-modified nanosheets
Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study
HIV-1 pretreatment and acquired antiretroviral drug resistance before tenofovir/ lamivudine /dolutegravir (TLD) roll-out in Mozambique
Drug-Induced Morphology Switch in Drug Delivery Systems Based on Poly(2-oxazoline)s
How to switch a master switch
HIV Treatment with the Two-Drug Regimen Dolutegravir Plus Lamivudine in Real-world Clinical Practice: A Systematic Literature Review
Switch Hitters
Comparing Real-World Healthcare Costs Associated with Single-Tablet Regimens for HIV-1: The 2-Drug Regimen Dolutegravir/Lamivudine vs. Standard 3- or 4-Drug Regimens
Analysis of patients’ request to switch from a generic drug to the original drug in external prescriptions
Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir Plus Lamivudine for Switch Therapy in Patients with HIV-1 Infection: A Real-World Cohort Study
Photothermal switch of drug release from polydopamine-modified nanosheets
Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study
HIV-1 pretreatment and acquired antiretroviral drug resistance before tenofovir/ lamivudine /dolutegravir (TLD) roll-out in Mozambique
Drug-Induced Morphology Switch in Drug Delivery Systems Based on Poly(2-oxazoline)s
How to switch a master switch
HIV Treatment with the Two-Drug Regimen Dolutegravir Plus Lamivudine in Real-world Clinical Practice: A Systematic Literature Review
Switch Hitters
Comparing Real-World Healthcare Costs Associated with Single-Tablet Regimens for HIV-1: The 2-Drug Regimen Dolutegravir/Lamivudine vs. Standard 3- or 4-Drug Regimens